Project Grant R21CA313262
Award Date 7/7/26
Completion Date 6/30/28
Dollars Obligated $399K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $656,285 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded June 22, 2026, with completion by May 31, 2031. This research project investigates incretin mimetics—specifically semaglutide and tirzepatide, two FDA-approved weight loss medications—as potential preventive interventions against obesity-related cancers, including...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $398,544 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded April 8, 2026, with completion targeted for March 31, 2028. This award supports pre-clinical evaluation of PRT3789, a highly selective SMARCA2 degrader, as a potential therapeutic intervention for therapy-resistant triple-negative breast cancer (TNBC). The...
- Grant Award Summary The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $658,093 Project Grant to the University of North Carolina at Chapel Hill effective July 13, 2026, with a completion date of June 30, 2031. This research initiative investigates mechanisms by which obesity drives endometrial cancer development and progression, with a focus on evaluating pharmacological and dietary weight-loss interventions as cancer...
- Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $411,152 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 5, 2025, with completion targeted for August 31, 2027. This research initiative focuses on identifying and validating noncovalent protein interactions of mutant KRAS (MKRAS) inhibitors, addressing a critical gap in understanding off-target effects of recently FDA-approved...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $135,951 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded September 4, 2025, with completion targeted for August 31, 2030. This grant supports research to enhance access to breast cancer prevention clinical trials, addressing well-documented barriers including insufficient population representation, limited awareness of...
- Federal Project Grant Award Summary Kaiser Foundation Hospitals, operating through its Kaiser Foundation Research Institute division as Kaiser Permanente, received a $733,410 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded August 1, 2026, with completion targeted for July 31, 2031. The research deliverable is a real-world epidemiological study evaluating the impact of incretin mimetics, specifically glucagon-like...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $1.47 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. This award supports research to identify and eliminate tumor regenerative cells (TRCs) that drive resistance to total neoadjuvant therapy (TNT) and metastatic recurrence in locally advanced rectal cancer (LARC). The research will deliver mechanistic...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $693,403 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on June 9, 2026, with performance through May 31, 2031. The award funds research to identify and inhibit novel downstream effectors of mutant KRAS (Kirsten rat sarcoma viral oncogene homolog) for targeted cancer therapy. The project addresses a critical gap in current...